iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Details Textual)

Stockholders' Equity (Details Textual) (USD $)	3 Months Ended	9 Months Ended		1 Months Ended	7 Months Ended
Stockholders' Equity (Details Textual) (USD $)	Mar. 31, 2015	Mar. 31, 2015	Mar. 31, 2014	Apr. 28, 2015	Mar. 31, 2015	Sep. 26, 2014	Jun. 30, 2014	Aug. 25, 2014
Stockholders' Equity [Line Items]
Preferred Stock, Shares Authorized	1,000,000us-gaap_PreferredStockSharesAuthorized	1,000,000us-gaap_PreferredStockSharesAuthorized			1,000,000us-gaap_PreferredStockSharesAuthorized		1,000,000us-gaap_PreferredStockSharesAuthorized
Common Stock, Shares Authorized	175,000,000us-gaap_CommonStockSharesAuthorized	175,000,000us-gaap_CommonStockSharesAuthorized			175,000,000us-gaap_CommonStockSharesAuthorized		175,000,000us-gaap_CommonStockSharesAuthorized
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	15,000,000	15,000,000			15,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0	1,636,000
Common Stock, Shares, Issued	74,070,958us-gaap_CommonStockSharesIssued	74,070,958us-gaap_CommonStockSharesIssued			74,070,958us-gaap_CommonStockSharesIssued		65,642,095us-gaap_CommonStockSharesIssued
Proceeds from Issuance of Common Stock		$ 7,302,000	$ 480,000
Proceeds from Warrant Exercises		867,000us-gaap_ProceedsFromWarrantExercises	3,100,000us-gaap_ProceedsFromWarrantExercises
Floor Price Of Common Stock						$ 0.20ibio_FloorPriceOfCommonStock
Stock Issued During Period, Value, New Issues		7,301,000
Payments of Stock Issuance Costs		0us-gaap_PaymentsOfStockIssuanceCosts	29,000us-gaap_PaymentsOfStockIssuanceCosts
Sale of Stock, Number of Shares Issued in Transaction	0.44
Warrant [Member]
Stockholders' Equity [Line Items]
Development Stage Entities, Stock Issued, Shares, Issued for Noncash Consideration	0	75,000
Common Stock [Member]
Stockholders' Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		6,600,000
Development Stage Entities, Stock Issued, Shares, Issued for Noncash Consideration	0	26,691
Stock Issued During Period, Shares, New Issues		6,084,000
Stock Issued During Period, Value, New Issues		6,000
Aspire Capital Fund, LLC [Member]
Stockholders' Equity [Line Items]
Aggregate Common Stock Purchased								10,000,000
Proceeds from Issuance of Common Stock	10,000,000			10,000,000
Stock Issued During Period, Shares, New Issues	6,084,354	6,084,000
Stock Issued During Period, Value, New Issues	7,301,786	7,301,000
Percentage Of Commitment Fee On Total Proceeds	3.00%
Payments of Stock Issuance Costs	300,000
Aspire Capital Fund, LLC [Member] \| Subsequent Event [Member]
Stockholders' Equity [Line Items]
Stock Issued During Period, Shares, New Issues		2,684,000
Stock Issued During Period, Value, New Issues		2,698,000
Aspire Capital Fund, LLC [Member] \| Subsequent Event [Member] \| Common Stock [Member]
Stockholders' Equity [Line Items]
Aggregate Common Stock Purchased	10,000,000	$ 10,000,000			$ 10,000,000
Sale of Stock, Number of Shares Issued in Transaction					2,684,452
Aspire Capital Fund, LLC [Member] \| Registration Rights Agreement [Member]
Stockholders' Equity [Line Items]
Sale of Stock, Price Per Share								$ 0.44